AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01738308 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Healing Touch Sham Treatment
Description: The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside
Study NCT01696578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BF-CBT and group physiotherapy
Description: Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
Study NCT01696578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BF-CBT and group physiotherapy
Description: Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
Study NCT02768194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: Dentifrice containing 0.454% stannous fluoride
Study NCT02768194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: Dentifrice containing 0.76% sodium monofluorophosphate
Study NCT02768194 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mineral water
Description: Commercially available mineral water
Study NCT02237976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Study NCT02237976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine practice
Study NCT03482323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.
Study NCT03482323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-Chi
Description: Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.
Study NCT00753935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enteric-coated aspirin
Description: enteric-coated aspirin 81mg daily for 2 weeks
Study NCT00753935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chewable aspirin
Description: chewable aspirin 81mg daily for 2 weeks
Study NCT02125006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
Study NCT00116857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline/omega-3
Description: Sertraline (50 mgs) plus omega-3 (2 grams)
Study NCT00116857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline/Corn Oil
Description: Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
Study NCT01603641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
Study NCT02112994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase Alfa
Description: IV infusion of sebelipase alfa
Study NCT01047761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity~Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises
Study NCT03477617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative Hemodynamic Algorithm
Description: Anesthesiologists are instructed to use the study's algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.
Study NCT03477617 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Usual hemodynamic management
Description: Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
Study NCT04121312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitation Intervention
Description: See arm description
Study NCT03071549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trichloroacetic acid peel
Description: Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
Study NCT03071549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined azaleic and salicylic acids
Description: Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
Study NCT03573128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Students with Autism Accessing General Education
Description: With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
Study NCT03573128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Services As Usual
Description: Teaching staff access in-service presentations and print materials with no active study team coaching.
Study NCT00916370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core size Xience Prime
Description: Core size includes a range of stent sizes.
Study NCT00916370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience Prime Long Lesion (LL)
Description: Long lesion stent sizes include a range of sizes.
Study NCT01346371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Tears 0.5% Lubricant Eye Drops
Study NCT01346371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bepreve 1.5% Ophthalmic Solution
Study NCT02011126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat Sodium
Description: Given IV
Study NCT01824745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive the SCP-BCS template booklet
Study NCT01824745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive the SCP-BCS template booklet
Study NCT01824745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Receive counseling sessions with a patient navigator
Study NCT01824745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Receive standard follow-up care
Study NCT01824745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01824745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01824745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01824745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00765934 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rapydan
Description: lidocaine / tetracaine 70/70 mg patch
Study NCT02011126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin therapy
Description: Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin therapy
Description: Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
Study NCT00547495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
Study NCT00547495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
Study NCT00547495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
Study NCT00547495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
Study NCT03668275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (partial) oncological home-hospitalization
Description: Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
Study NCT01194466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
Study NCT01194466 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
Study NCT02268253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp Injection
Description: Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.
Study NCT01102049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish, beef, fruit
Study NCT02537769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left ventricular assist device (LVAD)
Description: Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
Study NCT02537769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left ventricular assist device (LVAD)
Description: Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
Study NCT02921919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
Study NCT02537769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Repair (TVR)
Description: Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
Study NCT00687076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard of medical care for PAD
Study NCT00687076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard of medical care for PAD
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Daily dose of 325 mg of aspirin
Study NCT01194466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
Study NCT04470323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Lymphocyte subsets in peripheral blood were assessed by staining 50 µl of blood sample with 5 µl of Fluoroisothiocyanate (FITC)-conjugated- PD-1, phycoerythrin (PE)-conjugated-CD8, peridinium-chlorophyll-protein (Per-CP)-conjugated-CD4, Peridinium-chlorophyll-protein (Per-CP)-conjugated anti-CD3 and allophycocyanin (APC) conjugated anti-CD28.
Study NCT01206348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Description: Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
Study NCT04222439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI for the Diagnosis of Gastrointestinal Diseases
Description: After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
Study NCT03848221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: Systane Complete is an artificial tear.
Study NCT03848221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sensitive Eyes Rewetting Drops
Description: Sensitive Eyes Rewetting Drops is a rewetting drop.
Study NCT06068699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postcard
Description: Participants received a postcard asking them to address non-adherence to remote monitoring.
Study NCT01254019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968 6mg/kg/week
Description: subcutaneous
Study NCT03504072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 mg,
Description: tofacitinib 5 mg 12 hourly daily for 9 months
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Daily dose of 325 mg of aspirin
Study NCT03504072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
Study NCT02035735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WL and NBI
Description: For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
Study NCT05015374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: 350 mg/capsule (2mg Astaxanthin)
Study NCT05015374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04142619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCARTCS1A
Description: Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
Study NCT01131962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic control of hematemesis
Description: Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Niaspan
Description: Daily dose of 1500 mg of placebo Niaspan
Study NCT00687076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ezetimibe
Description: Daily dose of 10 mg of placebo Ezetimibe
Study NCT00687076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Description: Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
Study NCT00687076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Description: Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
Study NCT01842659 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Methylation Index
Description: To calculate the methylation index (MI) of imprinted regions.
Study NCT01203345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: The infants received their first dose of study drug within 24 hours of randomization.
Study NCT01203345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of 5 percent albumin solution
Study NCT01645176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine/Atorvastatin
Description: Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
Study NCT04419246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block
Description: ultrasound guided ultrasound guided interscalene block 30 minutes before operation. 30 minutes before operation.
Study NCT04419246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: 10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
Study NCT03061474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
Study NCT03061474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Oral Tablet
Study NCT00781196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: capsule 0.5 mg once a day
Study NCT00781196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule, once a day
Study NCT03516604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: PF-04995274 tablets
Study NCT03516604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram capsule
Study NCT03516604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet, identical to PF-04995274 tablet
Study NCT03516604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet, identical to PF-04995274 tablet
Study NCT03516604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsule, identical to citalopram capsule
Study NCT03516604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule, identical to citalopram capsule
Study NCT02361437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vasculera
Description: Vasculera 630 mg b.i.d.
Study NCT02361437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vasculera
Description: Vasculera 630 mg b.i.d.